Verenigde Staten - Engels - NLM (National Library of Medicine)

bedford laboratories - topotecan hydrochloride (unii: 956s425zcy) (topotecan - unii:7m7ykx2n15) - topotecan 4 mg in 4 ml - topotecan hydrochloride for injection is indicated for the treatment of:  - small cell lung cancer sensitive disease after failure of first-line chemotherapy. in clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy [see clinical studies (14) ].  - topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.  topotecan hydrochloride for injection is contraindicated in patients who have a history of severe hypersensitivity reactions (e.g., anaphylactoid reactions) to topotecan or to any of its ingredients. topotecan hydrochloride for injection should not be used in patients with severe bone marrow depression.  pregnancy category d [see

Malta - Engels - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

accord healthcare limited - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

accord healthcare limited - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - Engels - Medicines Authority

accord healthcare limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - topotecan - powder for concentrate for solution for infusion - topotecan 4 mg - antineoplastic agents

Australië - Engels - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - topotecan hydrochloride, quantity: 4.346 mg - injection, powder for - excipient ingredients: mannitol; tartaric acid; hydrochloric acid; sodium hydroxide - topotecan is indicated as single agent therapy for the treatment of patients with: - small cell lung carcinoma, after failure of first line chemotherapy. - metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - topotecan (as hydrochloride) - concentrate for solution for infusion - 1 milligram(s)/millilitre - other antineoplastic agents; topotecan

Canada - Engels - Health Canada

sandoz canada incorporated - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Ierland - Engels - HPRA (Health Products Regulatory Authority)

accord healthcare limited - topotecan (as hydrochloride) - concentrate for solution for infusion - 1 milligram(s)/millilitre - other antineoplastic agents; topotecan